全文获取类型
收费全文 | 16098篇 |
免费 | 2551篇 |
国内免费 | 371篇 |
专业分类
耳鼻咽喉 | 126篇 |
儿科学 | 715篇 |
妇产科学 | 361篇 |
基础医学 | 1489篇 |
口腔科学 | 194篇 |
临床医学 | 2056篇 |
内科学 | 4736篇 |
皮肤病学 | 324篇 |
神经病学 | 1317篇 |
特种医学 | 306篇 |
外科学 | 2141篇 |
综合类 | 1137篇 |
现状与发展 | 1篇 |
一般理论 | 5篇 |
预防医学 | 1485篇 |
眼科学 | 691篇 |
药学 | 796篇 |
2篇 | |
中国医学 | 189篇 |
肿瘤学 | 949篇 |
出版年
2024年 | 55篇 |
2023年 | 429篇 |
2022年 | 238篇 |
2021年 | 439篇 |
2020年 | 421篇 |
2019年 | 203篇 |
2018年 | 755篇 |
2017年 | 758篇 |
2016年 | 814篇 |
2015年 | 785篇 |
2014年 | 710篇 |
2013年 | 968篇 |
2012年 | 981篇 |
2011年 | 953篇 |
2010年 | 831篇 |
2009年 | 838篇 |
2008年 | 760篇 |
2007年 | 759篇 |
2006年 | 592篇 |
2005年 | 709篇 |
2004年 | 1154篇 |
2003年 | 967篇 |
2002年 | 743篇 |
2001年 | 665篇 |
2000年 | 289篇 |
1999年 | 328篇 |
1998年 | 361篇 |
1997年 | 292篇 |
1996年 | 136篇 |
1995年 | 98篇 |
1994年 | 83篇 |
1993年 | 105篇 |
1992年 | 90篇 |
1991年 | 52篇 |
1990年 | 60篇 |
1989年 | 59篇 |
1988年 | 56篇 |
1987年 | 45篇 |
1986年 | 38篇 |
1985年 | 22篇 |
1984年 | 20篇 |
1983年 | 20篇 |
1982年 | 19篇 |
1981年 | 22篇 |
1980年 | 14篇 |
1977年 | 13篇 |
1975年 | 13篇 |
1974年 | 18篇 |
1968年 | 17篇 |
1928年 | 13篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
CHEP Recommendations: Applying the 2005 Canadian Hypertension Education Program recommendations: 2. Assessing and reducing global atherosclerotic risk among hypertensive patients 下载免费PDF全文
22.
23.
The measurement of amniotic fluid (AF) acetylcholinesterase isoenzyme (AChEI) is a relatively new method for early diagnosis of open neural tube defects (NTDs). As quantitative methods are of unproven reliability at present, the authors used a high resolving power qualitative method-vertical slab polyaerylamide gel electrophoresis. The benefits of this technique are: simplicity of operation, accuracy, unsophisticated equipment, and easily available reagents. Combined results of 9 NTDs studies revealed that samples from early pregnancy gave more accurate results than those from late pregnancy. 相似文献
24.
Nhân Pham-Thi Pierre Scheinmann Riad Fadel Anne Combebias Claude Andre the Study Group 《Pediatric allergy and immunology》2007,18(1):47-57
Although several studies have demonstrated the efficacy of subcutaneous immunotherapy in allergic asthma, few have shown the same benefit using sublingual immunotherapy (SLIT) in asthmatic patients. This study was conducted to assess the efficacy of house dust mite (HDM) SLIT in addition to allergen avoidance and standard pharmacologic treatment. A double-blind, placebo-controlled trial was performed in 111 children (aged 5-15 yr) with HDM-induced mild-to-moderate asthma. After a 4-week baseline phase, patients were randomly assigned to receive SLIT with tablets of HDM extract (n = 55) or placebo (n = 56) for 18 months. Pharmacologic treatment was adjusted every 3 months following a step-down approach. Asthma symptom scores, reduction in use of inhaled corticosteroids and inhaled beta(2)-agonists, rhinitis symptoms, lung function tests, skin sensitivity to HDM, dust mite-specific immunoglobulin (Ig) E and IgG(4), and quality of life (QoL) were assessed during the study. After 18 months of treatment, diurnal and nocturnal asthma symptoms scores did not show significant differences between SLIT and placebo groups. Inhaled corticosteroids and inhaled beta(2)-agonists use was reduced in both groups without significant differences between groups. There were no significant differences in lung function (forced expiratory volume in 1 s and peak flow rate variations) between groups. Rhinitis symptom score decreased in both groups, with no difference between the two groups. The severity dimension of QoL was significantly improved in the SLIT group (age 6-12 yr). SLIT induced a significant reduction of skin sensitivity to HDM (p < 0.01) and a significant increase in HDM-specific IgE and IgG(4) antibodies (p < 0.001) in the SLIT group compared with the placebo group. SLIT was well tolerated with mild/moderate local adverse events. No severe systemic reactions were reported. This study indicates that, when mild-moderate asthmatic children are optimally controlled by pharmacologic treatment and HDM avoidance, SLIT does not provide additional benefit, despite a significant reduction in allergic response to HDM. Under such conditions, only a complete, but ethically unfeasible, discontinuation of inhaled corticosteroid would have demonstrated a possible benefit of SLIT. 相似文献
25.
F. Estelle R. Simons on Behalf of the Early Prevention of Asthma in Atopic Children Study Group 《Pediatric allergy and immunology》2007,18(6):535-542
There are more than 40 H(1)-antihistamines available worldwide. Most of these medications have never been optimally studied in prospective, randomized, double-masked, placebo-controlled trials in children. The aim was to perform a long-term study of levocetirizine safety in young atopic children. In the randomized, double-masked Early Prevention of Asthma in Atopic Children Study, 510 atopic children who were age 12-24 months at entry received either levocetirizine 0.125 mg/kg or placebo twice daily for 18 months. Safety was assessed by: reporting of adverse events, numbers of children discontinuing the study because of adverse events, height and body mass measurements, assessment of developmental milestones, and hematology and biochemistry tests. The population evaluated for safety consisted of 255 children given levocetirizine and 255 children given placebo. The treatment groups were similar demographically, and with regard to number of children with: one or more adverse events (levocetirizine, 96.9%; placebo, 95.7%); serious adverse events (levocetirizine, 12.2%; placebo, 14.5%); medication-attributed adverse events (levocetirizine, 5.1%; placebo, 6.3%); and adverse events that led to permanent discontinuation of study medication (levocetirizine, 2.0%; placebo, 1.2%). The most frequent adverse events related to: upper respiratory tract infections, transient gastroenteritis symptoms, or exacerbations of allergic diseases. There were no significant differences between the treatment groups in height, mass, attainment of developmental milestones, and hematology and biochemistry tests. The long-term safety of levocetirizine has been confirmed in young atopic children. 相似文献
26.
应用和推广烧伤皮肤再生医疗技术的体会(二) 总被引:1,自引:1,他引:0
杜福勤 《中国烧伤创疡杂志》2004,16(4):259-261
目的:通过临床实践总结、分析、认识干细胞与再生医学理论在烧伤创疡中的作用与效果;方法:应用MEBT/MEBO观察烧伤创疡创面的再生修复变化。结果:MEBT/MEBO治疗77种创疡疾病冶愈率达92%以上,有效率达100%。结论:MEBT/MEN)治疗慢性体表性溃疡及皮肤病性皮肤损伤、感染性溃疡效果满意。 相似文献
27.
28.
Utilization of care in haemophilia: a resource-based method for cost analysis from the Haemophilia Utilization Group Study (HUGS) 总被引:1,自引:0,他引:1
D. R. Globe R. G. Curtis† M. A. Koerper‡ For the HUGS Steering Committee§ 《Haemophilia》2004,10(S1):63-70
Summary. The Haemophilia Utilization Group Study (HUGS) was created 10 years ago to examine the annual utilization and cost of haemophilia-related healthcare services. Retrospective chart reviews for 336 patients with haemophilia A receiving treatment in one of five comprehensive haemophilia treatment centres (HTCs) during 1995 were completed through interview of the provider. This method provided adequate collection of data from patient charts without the abstractor having direct access to patient health information. Utilization data were used to impute the costs of different components of care (e.g. physician visits, factor VIII concentrate, emergency room, hospitalization). The total annual cost of care was $139 102 (SD $304 033). Factor VIII concentrate costs comprised the largest proportion of these costs; mean factor VIII concentrate use was 128 517 units per patient per year. Unbilled physician utilization accounted for 7.8% of the mean total physician costs per annum, while mean allied healthcare costs accounted for 33.5% of the total annual allied healthcare costs per patient. In the ordinary least-squares regression model, higher costs were associated with severe factor VIII deficiency, arthropathy, more comorbid conditions, an inhibitor to factor VIII concentrate, infusing through a port and prophylaxis. Although factor VIII concentrate is the most costly component, the treatment of haemophilia uses many healthcare resources. HUGS has demonstrated that patient clinical characteristics and physician practices predominantly drive the costs of haemophilia care. Specifically, patients with more severe arthropathy had greater healthcare costs. As future funding decisions are made, it is important to provide for all components of care. 相似文献
29.
30.
目的总结近20年来孤立性左肝胆管结石并发左肝胆管狭窄的临床治疗体会.方法原发性肝胆管结石1018例,年龄27~72岁,其中孤立性左肝胆管结石133例,手术治疗112例,对其临床资料进行回顾性分析,包括各肝管狭窄并发率,术前各项检查确诊率,手术治疗方式,再狭窄率.结果左肝管狭窄的发生率为598%,左外肝管和左内肝管分别为840%和848%,均以重度狭窄为主.狭窄切开整形后高位胆肠吻合术是处理左肝管狭窄的常用手术方式(522%),远期再狭窄率为171%;左半肝切除术施实率为194%,再狭窄率为00%;狭窄整形术和狭窄扩张术的施实率分别为90%和194%,再狭窄率分别为500%和923%.左外肝管狭窄通常采用肝段或肝叶切除术(787%),而左内肝管狭窄的处理则通常采用非左半肝切除术(848%).左内肝管狭窄的术前/后影像学确诊率明显低于左肝管和左外肝管,平均确诊率依次259%,933%和879%.结论二级肝管狭窄是孤立性左肝管结石的常见并发症,肝叶或肝段切除术是其首选治疗原则.过多依赖非肝叶/段切除术和不适当的肝段切除术是遗留狭窄和远期疗效差的重要原因 相似文献